Projahnmo Research Foundation

Projahnmo Research Foundation, a nonprofit organization based in Dhaka, Bangladesh, operates as a federal grant sub-recipient conducting collaborative implementation and intervention research studies in a Bangladeshi context, with all recent federal activity routed through Johns Hopkins University and Florida International University as prime grantees.

PRF's footprint is entirely sub-recipient grant work — three awards totaling $670 thousand in combined obligations across the National Institute of Child Health and Human Development (two awards) and the National Heart Lung and Blood Institute (one award), all issued between April 2025 and March 2026. The organization has not held federal prime grants or prime contracts. PRF's capability profile centers on epidemiological field research and intervention implementation in Bangladesh, including ethics approval coordination with the Bangladesh Medical Research Council, staff hiring and training, formative research conduct, baseline and endline survey execution, and embedded implementation within Bangladesh's government urban primary health care systems. Recent representative work includes sub-recipient roles on two linked awards supporting the BLAAST Trial (Bangladesh Lung Auscultation AI for Antibiotic Stewardship) through Johns Hopkins University, issued in April 2025 and January 2026, and a March 2026 sub-award from Florida International University focused on collaborative implementation research in Bangladesh's urban public health environment, where PRF facilitated integration with the government's Urban Primary Health Care Program and its partner organizations (Shimantik and Diabetes General Hospital for Sylhet city).

PRF reports established partnerships with leading U.S. academic research institutions — Johns Hopkins Bloomberg School of Public Health and Florida International University — as well as with global health organizations including the World Health Organization and the Gates Foundation. The organization's activity trajectory shows recent momentum: one award in 2025, two in 2026 year to date. No recompete exposure appears in the near term given the sub-recipient role and the recent award dates.